Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00331175 · ClinicalTrials.gov registry record · Phase 1
Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT00331175 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 31 participants.
The verdict
NCT00331175, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this trial is to evaluate the safety and tolerability of single escalating doses of Peptide YY3-36 and to determine effects on food intake and serum hormones when administered by intravenous infusion to otherwise healthy overweight adult subjects.
Interventions
- DRUG Peptide YY3-36
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2006-07 |
| Est. Completion | 2006-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00331175
The ClinicalTrials.gov registry entry for NCT00331175 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Peptide YY3-36 is the first listed.
NCT00331175 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00331175 about?
NCT00331175 is a clinical study titled "Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults". The purpose of this trial is to evaluate the safety and tolerability of single escalating doses of Peptide YY3-36 and to determine effects on food intake and serum hormones when administered by intravenous infusion to otherwise healthy overweight adult subjects.
What is the current status of trial NCT00331175?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2006-07. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00331175?
The interventions under investigation include: Peptide YY3-36 (DRUG).
Who is sponsoring clinical trial NCT00331175?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.